{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:01:56Z","timestamp":1789614116009,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"MCSP","award":["MCSP"],"award-info":[{"award-number":["MCSP"]}]},{"name":"DFG","award":["EXC 2145 SyNergy \u2013 ID 390857198"],"award-info":[{"award-number":["EXC 2145 SyNergy \u2013 ID 390857198"]}]},{"name":"F\u00f6FoLe","award":["Reg. No. 1287"],"award-info":[{"award-number":["Reg. No. 1287"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"DOI":"10.1007\/s00259-026-08182-w","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:08:15Z","timestamp":1789610895000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Baseline body composition and early PRRT outcome in GEP-NETs: an exploratory analysis"],"prefix":"10.1007","author":[{"given":"Elma","family":"Dema","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Dascalescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Holzgreve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens C.","family":"Cyran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam","family":"Widjaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz Josef","family":"Gildehaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix L.","family":"Herr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Spitzweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph J.","family":"Auernhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ingrisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Brendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Ricke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3175-952X","authenticated-orcid":false,"given":"Sophie Carina","family":"Siegmund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"8182_CR1","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/s1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, et al. (177)Lu-Dotatate plus long-acting octreotide versus high\u2013dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:1752\u201363. https:\/\/doi.org\/10.1016\/s1470-2045(21)00572-6.","journal-title":"Lancet Oncol"},{"key":"8182_CR2","doi-asserted-by":"publisher","first-page":"e13469","DOI":"10.1111\/jne.13469","volume":"37","author":"J Kuiper","year":"2025","unstructured":"Kuiper J, Zoetelief E, Brabander T, de Herder WW, Hofland J. Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours. J Neuroendocrinol. 2025;37:e13469. https:\/\/doi.org\/10.1111\/jne.13469.","journal-title":"J Neuroendocrinol"},{"key":"8182_CR3","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1007\/s11307-018-1252-5","volume":"21","author":"RA Werner","year":"2019","unstructured":"Werner RA, Ilhan H, Lehner S, Papp L, Zs\u00f3t\u00e9r N, Schatka I, et al. Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy. Mol Imaging Biol. 2019;21:582\u201390. https:\/\/doi.org\/10.1007\/s11307-018-1252-5.","journal-title":"Mol Imaging Biol"},{"key":"8182_CR4","doi-asserted-by":"publisher","first-page":"100017","DOI":"10.1016\/j.eanmj.2026.100017","volume":"3","author":"L Bodei","year":"2026","unstructured":"Bodei L, Gnanasegaran G, Giammarile F, Pavel M, Ambrosini V, Baum RP, et al. Joint EANM, IAEA, and SNMMI practical guidance on somatostatin receptor-targeted radionuclide therapy of neuroendocrine tumours. EANM J. 2026;3:100017. https:\/\/doi.org\/10.1016\/j.eanmj.2026.100017.","journal-title":"EANM J"},{"key":"8182_CR5","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s40618-024-02462-8","volume":"48","author":"S Massironi","year":"2025","unstructured":"Massironi S, Panzuto F, Zilli A, Rinzivillo M, Ciliberto A, Romano E, et al. Nutritional aspects in neuroendocrine neoplasms. bridging the gap between dietary interventions and cancer care strategies: a scoping review. J Endocrinol Investig. 2025;48:269\u201381. https:\/\/doi.org\/10.1007\/s40618-024-02462-8.","journal-title":"J Endocrinol Investig"},{"key":"8182_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/pros.24088","volume":"81","author":"S Sheikhbahaei","year":"2021","unstructured":"Sheikhbahaei S, Reyes DK, Rowe SP, Pienta KJ. CT-based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration-na\u00efve oligometastatic prostate cancer. Prostate. 2021;81:127\u201334. https:\/\/doi.org\/10.1002\/pros.24088.","journal-title":"Prostate"},{"key":"8182_CR7","doi-asserted-by":"publisher","first-page":"7937","DOI":"10.21037\/qims-24-365","volume":"14","author":"AI Garcia-Diez","year":"2024","unstructured":"Garcia-Diez AI, Porta-Vilaro M, Isern-Kebschull J, Naude N, Guggenberger R, Brugnara L, et al. Myosteatosis: diagnostic significance and assessment by imaging approaches. Quant Imaging Med Surg. 2024;14:7937\u201357. https:\/\/doi.org\/10.21037\/qims-24-365.","journal-title":"Quant Imaging Med Surg"},{"key":"8182_CR8","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1111\/ans.70222","volume":"95","author":"D Jia","year":"2025","unstructured":"Jia D, Shen X, Wang Z, Yang F, Ke N. Myosteatosis Is Associated With Overall Survival in Patients Receiving Pancreatectomy for Pancreatic Neuroendocrine Tumors. ANZ J Surg. 2025;95:1774\u201382. https:\/\/doi.org\/10.1111\/ans.70222.","journal-title":"ANZ J Surg"},{"key":"8182_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41430-021-00915-4","volume":"76","author":"DL Chan","year":"2022","unstructured":"Chan DL, Clarke SJ, Engel A, Diakos CI, Pavlakis N, Roach PJ, et al. Computed tomography (CT)-defined sarcopenia and myosteatosis are prevalent in patients with neuroendocrine neoplasms (NENs) treated with peptide receptor radionuclide therapy (PRRT). Eur J Clin Nutr. 2022;76:143\u20139. https:\/\/doi.org\/10.1038\/s41430-021-00915-4.","journal-title":"Eur J Clin Nutr"},{"key":"8182_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376:125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med"},{"key":"8182_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40644-020-00335-w","volume":"20","author":"DMV Huizing","year":"2020","unstructured":"Huizing DMV, Aalbersberg EA, Versleijen MWJ, Tesselaar MET, Walraven I, Lahaye MJ, et al. Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy. Cancer Imaging. 2020;20:57. https:\/\/doi.org\/10.1186\/s40644-020-00335-w.","journal-title":"Cancer Imaging"},{"key":"8182_CR12","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s10151-023-02769-3","volume":"27","author":"JEM Blackwell","year":"2023","unstructured":"Blackwell JEM, Herrod PJJ, Doleman B, Boyd-Carson H, Dolan D, Wheldon L, et al. CT-derived measures of muscle quantity and quality predict poorer outcomes from elective colorectal surgery: a UK multicentre retrospective cohort study. Tech Coloproctol. 2023;27:1091\u20138. https:\/\/doi.org\/10.1007\/s10151-023-02769-3.","journal-title":"Tech Coloproctol"},{"key":"8182_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.prnil.2018.04.002","volume":"7","author":"A Ohtaka","year":"2019","unstructured":"Ohtaka A, Aoki H, Nagata M, Kanayama M, Shimizu F, Ide H, et al. Sarcopenia is a poor prognostic factor of castration-resistant prostate cancer treated with docetaxel therapy. Prostate Int. 2019;7:9\u201314. https:\/\/doi.org\/10.1016\/j.prnil.2018.04.002.","journal-title":"Prostate Int"},{"key":"8182_CR14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1017\/s0029665118000046","volume":"77","author":"LE Daly","year":"2018","unstructured":"Daly LE, Prado CM, Ryan AM. A window beneath the skin: how computed tomography assessment of body composition can assist in the identification of hidden wasting conditions in oncology that profoundly impact outcomes. Proc Nutr Soc. 2018;77:135\u201351. https:\/\/doi.org\/10.1017\/s0029665118000046.","journal-title":"Proc Nutr Soc"},{"key":"8182_CR15","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.3390\/cancers18121987","volume":"18","author":"Y Deswysen","year":"2026","unstructured":"Deswysen Y, Trefois P, Danse E, Collard A, Van den Eynde M, Lanthier N. Integrated Assessment of Skeletal Muscle Quantity and Quality Is Associated with Survival in Patients with Oesophagogastric Malignancies: A Retrospective Cohort Study. Cancers. 2026;18:1987.","journal-title":"Cancers"},{"key":"8182_CR16","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1038\/s41598-023-31184-9","volume":"13","author":"K Bannangkoon","year":"2023","unstructured":"Bannangkoon K, Hongsakul K, Tubtawee T, Ina N, Chichareon P. Association of myosteatosis with treatment response and survival in patients with hepatocellular carcinoma undergoing chemoembolization: a retrospective cohort study. Sci Rep. 2023;13:3978. https:\/\/doi.org\/10.1038\/s41598-023-31184-9.","journal-title":"Sci Rep"},{"key":"8182_CR17","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3390\/cancers18060974","volume":"18","author":"NB Kumar","year":"2026","unstructured":"Kumar NB, Myosteatosis. A Distinct, Early and Targetable Novel Biomarker of Cancer Prognosis. Cancers. 2026;18:974.","journal-title":"Cancers"},{"key":"8182_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00432-025-06190-1","volume":"151","author":"A Surov","year":"2025","unstructured":"Surov A, Thormann M, Wienke A, Ricke J, Seidensticker M. Different cutoff values of the skeletal muscle mass and myosteatosis result in different clinical impact on overall survival in oncology. A subanalysis of a clinical trial. J Cancer Res Clin Oncol. 2025;151:141. https:\/\/doi.org\/10.1007\/s00432-025-06190-1.","journal-title":"J Cancer Res Clin Oncol"},{"key":"8182_CR19","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/jcsm.12538","volume":"11","author":"MP Chu","year":"2020","unstructured":"Chu MP, Li Y, Ghosh S, Sass S, Smylie M, Walker J, et al. Body composition is prognostic and predictive of ipilimumab activity in metastatic melanoma. J Cachexia Sarcopenia Muscle. 2020;11:748\u201355. https:\/\/doi.org\/10.1002\/jcsm.12538.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"8182_CR20","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/ueg2.12627","volume":"12","author":"A Surov","year":"2024","unstructured":"Surov A, Wienke A, Borggrefe J, Hinnerichs M, Seidensticker R, \u00d6cal O, et al. Skeletal muscle quality predicts overall survival in advanced liver hepatocellular carcinoma treated with SIRT and sorafenib: A subanalysis of the SORAMIC trial. United Eur Gastroenterol J. 2024;12:1016\u201327. https:\/\/doi.org\/10.1002\/ueg2.12627.","journal-title":"United Eur Gastroenterol J"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08182-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08182-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08182-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:08:16Z","timestamp":1789610896000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08182-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":20,"alternative-id":["8182"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08182-w","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"16 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This analysis was performed in compliance with the principles of the Declaration of Helsinki and was approved by the institutional ethics board of the LMU Munich (IRB #25\u20130233, #25\u20130131).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RAW: speaker honoraria for Novartis\/AAA. MB is a member of the Neuroimaging Committee of the EANM. MB has received speaker honoraria from Roche, GE Healthcare, Iba, Miltenyi, and Life Molecular Imaging; has advised Life Molecular Imaging, MIAC, Cenos, and GE healthcare; and is currently on the advisory or imaging review boards of AC Immune and ZRO Imaging. AH reported compensation for scientific consulting by ABX advanced biochemical compounds and for blinded reading by ABX\/Pharmtrace.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work the author(s) used Google-Assisted AI for language editing. After using this tool\/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.","order":4,"name":"Ethics","label":"Declaration of generative AI","group":{"name":"EthicsHeading","label":"Declarations"}}]}}